S55746 is primarily investigated for its potential in cancer therapy, particularly as a selective inhibitor of BCL-2 family proteins. It is being studied for its ability to induce apoptosis in cancer cells, making it a promising candidate for treating hematologic malignancies such as chronic lymphocytic leukemia and acute myeloid leukemia. Its application extends to overcoming resistance in cancer cells to conventional therapies, offering a new approach in targeted cancer treatment. Research is ongoing to evaluate its efficacy and safety in clinical settings.